Methods and compositions are disclosed utilizing the optically pure (+)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.

Sepracor Inc.

Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (+)-bupropion

Sepracor, Inc.

Methods and compositions for treating chronic disorders using optically pure (+)-bupropion

Disclosed is the compound (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and pharmaceutically acceptable salts and solvates thereof, pharmaceutical compositions comprising them, and processes for their preparation; also disclosed is a method of treating depression, attention deficit hyperactivity disorder (ADHD), obesity, migraine, pain, sexual dysfunction, Parkinson's disease, Alzheimer's disease, addiction to cocaine or tobacco products, seasonal affective disorder, chronic fatigue, narcolepsy or cognitive impairment using such compound, salts, solvates or compositions.

narcolepsy/nikotin

Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (+)-bupropion

Methods and compositions for treating chronic disorders using optically pure (+)-bupropion

Pharmaceutically active morpholinol

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen